An Analysis of the Sensitivity of the Activated Partial Thromboplastin Time (APTT) Assay, as Used in a Large Laboratory Network, to Coagulation Factor Deficiencies

被引:9
作者
Do, Louis [1 ,2 ]
Favaloro, Emmanuel [3 ,4 ]
Pasalic, Leonardo [3 ,4 ]
机构
[1] Westmead Hosp, Inst Clin Pathol & Med Res ICPMR, Westmead, NSW, Australia
[2] Westmead Hosp, Crown Princess Mary Canc Ctr, Westmead, NSW, Australia
[3] Westmead Hosp, Diagnost Haemostasis Lab, Westmead, NSW, Australia
[4] Westmead Hosp, Inst Clin Pathol & Med Res ICPMR, Westmead Diagnost Haemostasis Lab, NSW Hlth Pathol,Haematol, Westmead, NSW, Australia
关键词
APTT; Factor assay; Factor deficiency; Factor sensitivity; ONE-STAGE; HEMOSTASIS; STANDARDIZATION; GUIDELINES; REAGENTS; UPDATE;
D O I
10.1093/ajcp/aqac013
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives To advance knowledge in using the ex vivo method to identify factor sensitivity of the activated partial thromboplastin time (APTT), using data from a hemophilia and reference hemostasis laboratory; to evaluate application of inclusion and exclusion criteria to eliminate data outliers; and to discuss outcomes with reference to comparable studies. Methods An ex vivo, retrospective analysis was performed on patient samples with conjointly ordered APTT and intrinsic pathway factors (VIII, IX, XI, XII) for application to a large network of laboratories. The relationship between factor levels and APTT, before and after application of exclusion criteria, is demonstrated. Results Curvilinear relationships were found between all factor levels and APTTs, which demonstrated both similarities and differences with available studies. Factor sensitivity data are presented. Study strengths include large sample size and use of real-world data. Limitations include inability to exclude all residual outliers and paucity of patient samples singularly deficient in factors other than FVIII. Conclusions This ex vivo, retrospective analysis of the sensitivity of the APTT assay to intrinsic pathway factor deficiencies using real-world data from a hemophilia and reference hemostasis laboratory contains the largest sample size using this approach to date. The outcomes assist in informing practice in this area and can be used as a reference for further studies.
引用
收藏
页码:132 / 141
页数:10
相关论文
共 32 条
  • [1] [Anonymous], 2008, H47A2 CLSI
  • [2] [Anonymous], 2008, DEFINING ESTABLISHIN
  • [3] New approaches for measuring coagulation
    Barrowcliffe, TW
    Cattaneo, M
    Podda, GM
    Bucciarelli, P
    Lussana, F
    Lecchi, A
    Toh, CH
    Hemker, HC
    Béguin, S
    Ingerslev, J
    Sorensen, B
    [J]. HAEMOPHILIA, 2006, 12 : 76 - 81
  • [4] Begbie M, 2000, THROMB HAEMOSTASIS, V84, P216
  • [5] Clinical and Laboratory Standards Institute (CLSI), 2016, DET COAG FACT ACT US
  • [6] CLSI, 2014, H60A CLSI
  • [7] College of American Pathologists, HEM COAG CHECKL
  • [8] Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis Update of the guidelines for lupus anticoagulant detection and interpretation
    Devreese, Katrien M. J.
    de Groot, Philip G.
    de Laat, Bas
    Erkan, Doruk
    Favaloro, Emmanuel J.
    Mackie, Ian
    Martinuzzo, Marta
    Ortel, Thomas L.
    Pengo, Vittorio
    Rand, Jacob H.
    Tripodi, Armando
    Wahl, Denis
    Cohen, Hannah
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (11) : 2828 - 2839
  • [9] Escobar M A., 2019, Less common congenital disorders of hemostasis, P59
  • [10] Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors
    Favaloro, EJ
    Soltani, S
    McDonald, J
    Grezchnik, E
    Easton, L
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2005, 16 (08) : 597 - 605